Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
DiaSorin SpA management to meet virtually with Berenberg » 04:55
09/25/20
09/25
04:55
09/25/20
04:55
DSRLF

DiaSorin SpA

$0.00 /

+ (+0.00%)

Virtual Meetings to be…

Virtual Meetings to be held on September 24-25 hosted by Berenberg.

ShowHide Related Items >><<
DSRLF DiaSorin SpA
$0.00 /

+ (+0.00%)

DSRLF DiaSorin SpA
$0.00 /

+ (+0.00%)

06/04/20 Berenberg
DiaSorin SpA price target raised to EUR 160 from EUR 145 at Berenberg
05/26/20 Jefferies
DiaSorin SpA downgraded to Underperform from Hold at Jefferies
03/17/20 Berenberg
DiaSorin SpA price target lowered to EUR 110 from EUR 113 at Berenberg
Over a month ago
Conference/Events
DiaSorin SpA management to meet virtually with Berenberg » 04:55
09/24/20
09/24
04:55
09/24/20
04:55
DSRLF

DiaSorin SpA

$0.00 /

+ (+0.00%)

Virtual Meetings to be…

Virtual Meetings to be held on September 24-25 hosted by Berenberg.

ShowHide Related Items >><<
DSRLF DiaSorin SpA
$0.00 /

+ (+0.00%)

DSRLF DiaSorin SpA
$0.00 /

+ (+0.00%)

06/04/20 Berenberg
DiaSorin SpA price target raised to EUR 160 from EUR 145 at Berenberg
05/26/20 Jefferies
DiaSorin SpA downgraded to Underperform from Hold at Jefferies
03/17/20 Berenberg
DiaSorin SpA price target lowered to EUR 110 from EUR 113 at Berenberg
Conference/Events
DiaSorin SpA management to meet virtually with Berenberg » 14:33
09/18/20
09/18
14:33
09/18/20
14:33
DSRLF

DiaSorin SpA

$0.00 /

+ (+0.00%)

Virtual Meetings to be…

Virtual Meetings to be held on September 24-25 hosted by Berenberg.

ShowHide Related Items >><<
DSRLF DiaSorin SpA
$0.00 /

+ (+0.00%)

DSRLF DiaSorin SpA
$0.00 /

+ (+0.00%)

06/04/20 Berenberg
DiaSorin SpA price target raised to EUR 160 from EUR 145 at Berenberg
05/26/20 Jefferies
DiaSorin SpA downgraded to Underperform from Hold at Jefferies
03/17/20 Berenberg
DiaSorin SpA price target lowered to EUR 110 from EUR 113 at Berenberg
Hot Stocks
DiaSorin, MeMed partner to develop, commercialize diagnostics solution » 07:13
09/08/20
09/08
07:13
09/08/20
07:13
DSRLF

DiaSorin SpA

$0.00 /

+ (+0.00%)

DiaSorin and MeMed have…

DiaSorin and MeMed have announced the creation of a strategic partnership to accelerate the deployment of a novel, host-protein signature-based assay. Under the terms of the agreement, DiaSorin has obtained the rights to commercialize the proprietary MeMed BV test on its LIAISONO family of analyzers and, through this partnership, DiaSorin and MeMed will make the MeMed BV test available on over 5,000 LIAISONO XL and LIAISONO XS platforms installed worldwide. A pioneer in the field of host immune response, MeMed developed MeMed BV, a technology that integrates machine learning with measurements of three key host-immune proteins: tumor necrosis factor-related apoptosis-inducing ligand, interferon gamma induced protein-10 , and C-reactive protein. The MeMed solution enables physicians to differentiate accurately between bacterial and viral infections, thus supporting fast and better-informed treatment and patient management decisions. Distinguishing between bacterial and viral etiologies in acute infections has been a universal challenge for health care providers. Current practices such as medical history, physical findings and other medical tests provide incomplete answers. Failing to recognize the trigger of an infection may significantly alter the whole trajectory of patient care, including but not limited to the inappropriate use of antimicrobials that contribute to the growing global threat posed by antimicrobial resistance. Therefore, there is a pressing need for access to reliable and rapid information to aid clinicians in distinguishing between bacterial and viral infections in order to better manage their patients. MeMed BV was developed and extensively validated by numerous collaborations carried-out by MeMed with leading academic centers and commercial partners, and has the potential to aid in transforming patient management. The test is backed by large high-quality, real-world data from over 15,000 patients, in addition to multinational, double-blind clinical studies, showing over 90% sensitivity and specificity in differentiating bacterial vs viral infections. MeMed BV was CE marked and has received AMAR clearance from the Israeli Ministry of Health.

ShowHide Related Items >><<
DSRLF DiaSorin SpA
$0.00 /

+ (+0.00%)

06/04/20 Berenberg
DiaSorin SpA price target raised to EUR 160 from EUR 145 at Berenberg
05/26/20 Jefferies
DiaSorin SpA downgraded to Underperform from Hold at Jefferies
03/17/20 Berenberg
DiaSorin SpA price target lowered to EUR 110 from EUR 113 at Berenberg
Over a quarter ago
Recommendations
DiaSorin SpA price target raised to EUR 160 from EUR 145 at Berenberg » 14:25
06/04/20
06/04
14:25
06/04/20
14:25
DSRLF

DiaSorin SpA

$0.00 /

+ (+0.00%)

Berenberg analyst Scott…

Berenberg analyst Scott Bardo raised the firm's price target on DiaSorin SpA to EUR 160 from EUR 145 and keeps a Hold rating on the shares.

ShowHide Related Items >><<
DSRLF DiaSorin SpA
$0.00 /

+ (+0.00%)

05/26/20 Jefferies
DiaSorin SpA downgraded to Underperform from Hold at Jefferies
03/17/20 Berenberg
DiaSorin SpA price target lowered to EUR 110 from EUR 113 at Berenberg
Downgrade
DiaSorin SpA downgraded to Underperform from Hold at Jefferies » 06:37
05/26/20
05/26
06:37
05/26/20
06:37
DSRLF

DiaSorin SpA

$0.00 /

+ (+0.00%)

Jefferies analyst Peter…

Jefferies analyst Peter Welford downgraded DiaSorin SpA to Underperform from Hold with a price target of EUR 120, up from EUR 101. While acknowledging the scarcity value of an Italian mid-sized healthcare and diagnostic company with COVID-19 tests and the impact of the recent short-sale ban, Welford cannot justify DiaSorin's current valuation and advises locking in profits, he tells investors. He also has concerns that the ongoing pandemic may not fundamentally change the company's mid-to-long term dynamics.

ShowHide Related Items >><<
DSRLF DiaSorin SpA
$0.00 /

+ (+0.00%)

03/17/20 Berenberg
DiaSorin SpA price target lowered to EUR 110 from EUR 113 at Berenberg
Recommendations
DiaSorin SpA price target lowered to EUR 110 from EUR 113 at Berenberg » 10:24
03/17/20
03/17
10:24
03/17/20
10:24
DSRLF

DiaSorin SpA

$0.00 /

+ (+0.00%)

Berenberg analyst Scott…

Berenberg analyst Scott Bardo lowered the firm's price target on DiaSorin SpA to EUR 110 from EUR 113 and keeps a Hold rating on the shares. While the analyst sees coronavirus as a net negative to business performance, the analyst believes the company's fundamentals are robust.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.